Patrick Heron
Managing Partner at Frazier Life Sciences
Menlo Park, California
Overview
Work Experience
Board Observer
2024 - Current
Board Chair
2022
Board Member
2021
HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Raised $235,000,000.00 from Deerfield, Abingworth, Greenspring Associates, RA Capital Management, Catalys Pacific, Richard King Mellon Foundation, Qiming Venture Partners USA, Perceptive Advisors, Biotechnology Value Fund and Lightspeed Venture Partners.
Managing Partner
1999
Frazier Life Sciences invests globally in private and publicly-traded companies that discover and commercialize biopharmaceuticals.
Board Member
2020
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Raised $238,400,000.00 from OrbiMed, New Enterprise Associates, Wellington Management, Frazier Life Sciences, Norwest Venture Partners, Deep Track Capital, Driehaus Capital Management, T. Rowe Price and RA Capital Management.
Board Observer
2020
Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies.
Raised $272,000,000.00 from California Institute for Regenerative Medicine.
Investment Committee Member - Strategic Investment Fund
2020
Bill & Melinda Gates Foundation supports initiatives in education, world health and population, and community giving.
Chairman Of The Board
2017
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Raised $833,500,000.00 from SLR Capital Partners.
Board Member
2018
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Raised $497,000,000.00 from Oberland Capital.
Board Member
2022 - 2023